Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Nov 2019
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). ⋯ In this post hoc analysis of patients with UC, during tofacitinib exposure, one patient had DVT and four had PE, all during the OLE study, on predominant dose 10 mg b.d. (83% of overall cohort patients received predominant dose 10 mg b.d.) with venous thromboembolism risk factors. This analysis is limited by small sample size and limited drug exposure; further studies are needed. ClinicalTrials.gov: NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612.
-
Aliment. Pharmacol. Ther. · Nov 2019
Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients.
Severe and fulminant Clostridioides difficile infection is associated with high mortality rates. While faecal microbiota transplant has been shown to be effective for recurrent C difficile infection, there is little data on the utility of faecal microbiota transplant in severe or fulminant C difficile infection. ⋯ Faecal microbiota transplantation provides mortality benefit over standard of care for severe and fulminant C difficile infection and should be considered in critically ill patients.
-
Aliment. Pharmacol. Ther. · Oct 2019
ReviewReview article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects.
Immune checkpoint inhibitors have revolutionised the oncological landscape in the last few years. Possible applications include the treatment of hepatocellular carcinoma and cholangiocarcinoma. Unfortunately, new immune-related adverse effects have been associated with the use of these agents and the liver is one of the organs most frequently involved. ⋯ Immune checkpoint inhibitors represent an exciting new class of drugs with currently limited application in malignant and non-malignant liver disease. Caution must be exercised on the emergence of potentially severe immune adverse reactions.
-
Aliment. Pharmacol. Ther. · Sep 2019
Depression is associated with non-alcoholic fatty liver disease among adults in the United States.
Currently, the relationship between depression and non-alcoholic fatty liver disease (NAFLD) is not clearly defined. ⋯ In a nationally representative sample of US adults, depression was independently associated with NAFLD.